Last reviewed · How we verify
Gemcitabine & oxaliplatin
Gemcitabine and oxaliplatin are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, with gemcitabine acting as a nucleoside analog and oxaliplatin forming platinum-DNA crosslinks.
Gemcitabine and oxaliplatin are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, with gemcitabine acting as a nucleoside analog and oxaliplatin forming platinum-DNA crosslinks. Used for Pancreatic cancer, Biliary tract cancer, Gastric cancer.
At a glance
| Generic name | Gemcitabine & oxaliplatin |
|---|---|
| Also known as | Active Comparator |
| Sponsor | 3D Medicines (Sichuan) Co., Ltd. |
| Drug class | Chemotherapy combination (nucleoside analog + platinum agent) |
| Target | DNA (gemcitabine via ribonucleotide reductase inhibition and DNA incorporation; oxaliplatin via platinum-DNA adducts) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a deoxycytidine analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. Oxaliplatin is a third-generation platinum compound that forms interstrand and intrastrand DNA crosslinks, preventing DNA replication and transcription. The combination leverages synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Pancreatic cancer
- Biliary tract cancer
- Gastric cancer
- Non-small cell lung cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Peripheral neuropathy
- Fatigue
- Diarrhea
- Mucositis
- Hepatotoxicity
Key clinical trials
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |